Trending...
- Charmaine Thompson Turns Pain Into Purpose Through Woman of Power Charmcare
- Phinge Exposes Massive AI Security Risks, Claiming Its Patented Hardware-Verified Architecture Is The Only Safeguard Against Surveillance Capitalism
- Permian Museum announces the addition of an Ancient Alien Artifacts photo gallery
HORSHAM, Pa.--(BUSINESS WIRE)--Myonex, a leading global clinical trial supply company, announces the launch of the first and only on-demand local drug sourcing in Europe. Built on a successful North American program, CTRx Europe offers significant benefits for trial sponsors, sites, and patients alike.
"With the growth of our CTRx service in North America, clients have been asking us to develop the same solution for them in Europe. Our new CTRx Europe solution is a game-changer for clinical sites in Europe," said James Lovett, Chief Executive Officer at Myonex. "Our solution will offer support for sites to source local drug for local patients, in individual European countries. Sponsors can remove overage and eliminate costs associated with up-front bulk comparator purchases, inventory management, and expired drugs. The program has delivered tremendous results in the United States and Canada, and we are pleased to be able to offer similar flexibility and savings in Europe."
More on The PennZone
Through its partnerships with central dispensing pharmacies in major European markets, Myonex can offer on-demand local sourcing. The CTRx solution provides sponsors with in-country local pricing and access to key oncology and other specialty medications and hospital lines. Sites need less storage space and fewer resources, so they can accommodate more trials. Sponsors can track dispensing via a secure, GDPR-compliant portal, and sites can request orders online.
Myonex's CTRx solution supports traditional, decentralized, and hybrid trials. In processes tailored to meet local regulations, both sponsor investigational medicinal products and commercial drugs, as well as ancillary items, can be delivered directly to the clinical site, central nursing center, a nurse, or even to the patient's home.
"The direct-to-patient offering makes adherence easier," said Samit Bhatt, Senior Director, Clinical Trial Patient Solutions, at Myonex. "And because our local partners serve local markets, logistics costs per patient and site shipment are lower, and sponsors can see significantly improved study start-up time."
More on The PennZone
CTRx Europe is part of an end-to-end suite of clinical trial supply solutions from Myonex that also includes expanded packaging and labeling capabilities; warehousing, storage, and distribution; project management and more. For information, email globalsales@myonex.com.
About Myonex
Myonex is a leading global clinical trial supply company with more than 30 years of experience supporting sponsors that range from Big Pharma to small biotech, as well as CROs, and other service providers. Its four unique services—sourcing, packaging/labeling, ancillaries and patient solutions—work together to create flexibility, improve effectiveness, increase efficiency and eliminate waste. The company problem-solves and tailors solutions to the specific requirements and complexities of each trial, and sponsors and CROs benefit from the simplicity of having a single vendor that can provide an optimized, integrated clinical trial supply strategy that saves time and money. Learn more at www.myonex.com.
Contacts
Maryanne Walsh
+1 267-307-0876
"With the growth of our CTRx service in North America, clients have been asking us to develop the same solution for them in Europe. Our new CTRx Europe solution is a game-changer for clinical sites in Europe," said James Lovett, Chief Executive Officer at Myonex. "Our solution will offer support for sites to source local drug for local patients, in individual European countries. Sponsors can remove overage and eliminate costs associated with up-front bulk comparator purchases, inventory management, and expired drugs. The program has delivered tremendous results in the United States and Canada, and we are pleased to be able to offer similar flexibility and savings in Europe."
More on The PennZone
- LCC Asia Pacific Sponsors CubeSatPlus 2026 at UNSW Sydney
- Kellyn Endorses National Push to Expand Food is Medicine
- LATO AI Automates Customer Communication to Help CSide Sports Academy and BAT 24 Nation Grow
- Real Estate Syndication Attorney Tilden Moschetti Releases The Real Estate Private Equity Blueprint
- 5X Gross Margin Improvement to Beat EPS Consensus; $54.6 Million 10-Year Contract Award Puts Cybersecurity Leader on Path to a $30 Million Run Rate
Through its partnerships with central dispensing pharmacies in major European markets, Myonex can offer on-demand local sourcing. The CTRx solution provides sponsors with in-country local pricing and access to key oncology and other specialty medications and hospital lines. Sites need less storage space and fewer resources, so they can accommodate more trials. Sponsors can track dispensing via a secure, GDPR-compliant portal, and sites can request orders online.
Myonex's CTRx solution supports traditional, decentralized, and hybrid trials. In processes tailored to meet local regulations, both sponsor investigational medicinal products and commercial drugs, as well as ancillary items, can be delivered directly to the clinical site, central nursing center, a nurse, or even to the patient's home.
"The direct-to-patient offering makes adherence easier," said Samit Bhatt, Senior Director, Clinical Trial Patient Solutions, at Myonex. "And because our local partners serve local markets, logistics costs per patient and site shipment are lower, and sponsors can see significantly improved study start-up time."
More on The PennZone
- Tina Hasselbusch, Turnstone Creative Co-founder and Chief Executive Officer, Named to LVB 300
- Pittsburgh Family Law Attorneys at Pollock Begg Earn Top Honors in 2027 Best Lawyers Guide
- Independent Colbert Packaging Thrives Amid Industrywide Consolidation
- Free Commercial Glass Estimating and Code Compliance Tools Launched by Landmark Construction - The Leading Glass Company in Los Angeles
- Tallahassee Million-Dollar Home Sales Rise in 2026 as Median Selling Time More Than Doubles
CTRx Europe is part of an end-to-end suite of clinical trial supply solutions from Myonex that also includes expanded packaging and labeling capabilities; warehousing, storage, and distribution; project management and more. For information, email globalsales@myonex.com.
About Myonex
Myonex is a leading global clinical trial supply company with more than 30 years of experience supporting sponsors that range from Big Pharma to small biotech, as well as CROs, and other service providers. Its four unique services—sourcing, packaging/labeling, ancillaries and patient solutions—work together to create flexibility, improve effectiveness, increase efficiency and eliminate waste. The company problem-solves and tailors solutions to the specific requirements and complexities of each trial, and sponsors and CROs benefit from the simplicity of having a single vendor that can provide an optimized, integrated clinical trial supply strategy that saves time and money. Learn more at www.myonex.com.
Contacts
Maryanne Walsh
+1 267-307-0876
0 Comments
Latest on The PennZone
- GGILabs Expands Local SEO Services to Help Businesses Compete in AI-Driven Search
- Sara Viteri, Turnstone Creative Senior Producer, Named to Lehigh Valley Business' Forty Under 40
- Boyertown Mechanic Travels to Nashville to Learn How AI Is Changing Auto Repair
- Colonial Nissan Earns Capital One Top Performing Dealership Award
- BlazeHive's AI SEO Agent Outranks Human Writers on 500+ Google Top-3 Results in 5 Months, on Autopilot
- Logistics Expert Asks A Question Biology Has Overlooked: How Evolution Assembles Coordinated Novelty
- Phinge Exposes Massive AI Security Risks, Claiming Its Patented Hardware-Verified Architecture Is The Only Safeguard Against Surveillance Capitalism
- Phinge & CEO Robert DeMaio Publicly Declare Cash Settlements or Judgments Alone Cannot & Will Not Remedy the Deep Public Harm of Infringing Its IP
- Dana Flanagan Expands the Authority Architect, Bringing a Nontraditional Approach to Executive Authority, Strategic Access and Business Growth
- Phinge's Netverse: Reclaiming the Digital Frontier For Everyone Through CEO Robert DeMaio's Vision of a True App-less, User Data Sovereign World
- DuraFast Label Company Launches Seiko SLP850 2" Thermal Printer with Free Label Promotion
- Scientific Figure Releases Free Layout Template Libraries for Graphical Abstracts and Research Posters
- Permian Museum announces the addition of an Ancient Alien Artifacts photo gallery
- Philly Tailgates Announces Full 2026 Eagles Season Schedule, Opening With Back-to-back Events
- The Golden Jazz Fest Shuttle Returns for 2026
- KeysCaribbean Resorts Offer Savings On Vacations Through Aug. 31, Preview Exceptional Select Fall Rates of Less Than $200/Night
- Fit Body Boot Camp Launches Nationwide 'Fit Body Forever' Workshops to Help Adults 60+ Rebuild Strength and Prevent Falls
- Canadian Aerospace Defence Talent Expo (CADTE) Launches National TalentThread Initiative to Strengthen Canada's Future Workforce
- 5.6 Million EUR in Q1 Project Awards for Integrated IoT Solutions / Data Analytics Subsidiary of Smart City Developer: Affluence (Stock Symbol: AFFU)
- Merger Advancement For Embodied AI Co in Robotic Systems Serving High Value Hospitality, Gaming & Real Estate Sectors: MBody AI Corp. (NAS DAQ: MBAI)